Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression.

ABSTRACT:

Background

The benefits and risks of augmenting or switching antidepressants in older adults with treatment-resistant depression have not been extensively studied.

Methods

We conducted a two-step, open-label trial involving adults 60 years of age or older with treatment-resistant depression. In step 1, patients were randomly assigned in a 1:1:1 ratio to augmentation of existing antidepressant medication with aripiprazole, augmentation with bupropion, or a switch from existing antidepressant medication to bupropion. Patients who did not benefit from or were ineligible for step 1 were randomly assigned in step 2 in a 1:1 ratio to augmentation with lithium or a switch to nortriptyline. Each step lasted approximately 10 weeks. The primary outcome was the change from baseline in

SUBMITTER: Lenze EJ 

PROVIDER: S-EPMC10568698 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature